- Home
- KALU vs PCRX Comparison
KALU vs PCRX Comparison
Compare KALU & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALU
- PCRX
- Stock Information
- Founded
- KALU 1946
- PCRX 2006
- Country
- KALU United States
- PCRX United States
- Employees
- KALU 3900
- PCRX N/A
- Industry
- KALU Metal Fabrications
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- KALU Industrials
- PCRX Health Care
- Exchange
- KALU Nasdaq
- PCRX Nasdaq
- Market Cap
- KALU 1.5B
- PCRX 1.2B
- IPO Year
- KALU 1991
- PCRX 2011
- Fundamental
- Price
- KALU $93.94
- PCRX $23.15
- Analyst Decision
- KALU Buy
- PCRX Strong Buy
- Analyst Count
- KALU 3
- PCRX 6
- Target Price
- KALU $95.67
- PCRX $33.83
- AVG Volume (30 Days)
- KALU 169.2K
- PCRX 740.7K
- Earning Date
- KALU 10-22-2025
- PCRX 11-06-2025
- Dividend Yield
- KALU 3.36%
- PCRX N/A
- EPS Growth
- KALU 58.01
- PCRX N/A
- EPS
- KALU 5.17
- PCRX 0.47
- Revenue
- KALU $3,209,400,000.00
- PCRX $716,791,000.00
- Revenue This Year
- KALU $12.83
- PCRX $7.27
- Revenue Next Year
- KALU $12.98
- PCRX $10.18
- P/E Ratio
- KALU $17.75
- PCRX $48.91
- Revenue Growth
- KALU 7.69
- PCRX 3.14
- 52 Week Low
- KALU $46.81
- PCRX $16.29
- 52 Week High
- KALU $97.63
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- KALU 58.56
- PCRX 49.99
- Support Level
- KALU $88.58
- PCRX $22.29
- Resistance Level
- KALU $92.39
- PCRX $24.95
- Average True Range (ATR)
- KALU 3.11
- PCRX 1.26
- MACD
- KALU -0.62
- PCRX 0.11
- Stochastic Oscillator
- KALU 56.18
- PCRX 61.12
About KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.